Finanzen von enGene Therapeutics Inc (ENGN)ENGNenGene Therapeutics Inc

Evaluating the bottom line, enGene Therapeutics Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -52.58%, provide a clear picture of how effectively ENGN converts its operational activities into shareholder value.

In the context of the broader market, ENGN competes directly with industry leaders such as DOYU and TISI. With a market capitalization of $130.63M, it holds a significant position in the sector. When comparing efficiency, ENGN's gross margin of N/A stands against DOYU's 16.21% and TISI's 25.10%. Such benchmarking helps identify whether enGene Therapeutics Inc. is trading at a premium or discount relative to its financial performance.

enGene has been experiencing substantial net losses, with Q2 2026 showing a loss of $30.23 million, and an EPS of -0.43. The company's financial health is under pressure, with a current ratio of 12.57 indicating good liquidity, but ongoing losses are a concern.